DERMIRA INC. overview

SHAREHOLDER ALERT: WeissLaw LLP Investigates Dermira, Inc. PR Newswire NEW YORK, Jan. 10, 2020 NEW YORK , Jan. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dermira, Inc. ("DERM" or the "Company") (NASDAQ: DERM) in connection with the proposed acquisition of the Company by Eli Lilly and Company ("LLY") (NYSE: LLY). Under the terms of the acquisition agreement, DERM shareholders will receive...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of DERMIRA, INC. - DERM PR Newswire NEW YORK, Jan. 10, 2020 NEW YORK , Jan. 10, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Dermira, Inc. ("Dermira" or the "Company") (Nasdaq: DERM) relating to the sale of the Company to Eli Lilly and Company. Under the terms of...

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on December 9, 2019, the company granted inducement awards to 11 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were...

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for lebrikizumab, its novel, investigational treatment being evaluated for patients with moderate-to-severe atopic dermatitis. Fast Track is a designation granted by the...

...

...

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that detailed primary results from its Phase 2b dose-ranging study of lebrikizumab are being presented during the 39 th Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult...

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that detailed primary results of its Phase 2b study of lebrikizumab in patients with moderate-to-severe atopic dermatitis will be reported at the 39 th Annual Fall Clinical Dermatology Conference in Las Vegas, NV, October 17-20, 2019. In addition, the...